Some investors are not interested in excitement. They can be found at retirement seminars, in dentist offices looking through old copies of Barron’s, or on Reddit threads where a sincere person asks if it’s still worthwhile to own a stock that hasn’t moved much in three years. They’re not trying to find the next Nvidia. A check is what they want. every three months. predictable. boring enough to be disregarded.
For many years, Johnson & Johnson has been the crowd’s patron saint. Furthermore, it’s difficult to ignore how polarized people have become regarding the definition of “passive income” in 2026 when observing the discourse surrounding JNJ. Yield is what some desire. Some people desire security. Depending on your goals, JNJ’s strong tendency toward the second camp may be a strength or a weakness.
You could do the math at the dinner table. If you invest $5,000 in JNJ at the current price of about $224, you will have about 22 shares. At the current $1.34 quarterly payout, those shares throw off roughly $119 annually. Not transformative. However, it appears. Every three months. Whether the market is freaking out over something it will have forgotten by Thanksgiving, the Fed is cutting, or the talc lawsuits are intensifying.
The most frequently quoted section is the streak, and for good reason. With 64 years of dividend increases in a row, J&J is in a unique position. The business is one of just two American companies with a AAA credit rating. Go over that sentence once more. The debt rating of the US government is lower. The bond market’s perception of a company that sells surgical staplers, knee replacements, and cancer medications in almost every nation on the planet can be inferred from that particular detail.
However, the skepticism is genuine and deserving of serious consideration. On investment forums, people will point out that the stock has looked drowsy for periods of time, that the five-year price return has been modest, and that the talc litigation is still ongoing. A high-yield savings account is not far off, as one Redditor stated bluntly last year. If you’re measuring on a short clock, you have a valid point. If you’re not, it misses something.
Because dividend investing is a long game that appears to be slow when done seriously. Recently, a doctor on YouTube calculated the returns on a $10,000 investment made in J&J in 2006. These days, that job pays out more than $800 annually—not from heroic capital appreciation, but rather from twenty years of consecutive raises piling on top of one another. That’s the subtle compounding that no one writes about in a headline.
The first quarter of 2026 demonstrated the continued viability of the underlying business. Oncology medications like Darzalex and Carvykti drove revenue growth of almost 10% year over year, and the medtech cardiovascular division easily withstood pressure from biosimilars on Stelara. In order to keep the pipeline stocked for the next ten years, the company has been investing heavily in R&D, spending more than $17 billion annually, and free cash flow continues to easily cover the dividend.
Observing all of this gives me the impression that JNJ stands for an investment strategy that has become outdated but is still relevant. Nobody will become wealthy very quickly. It’s unlikely to be the stock you boast about at social gatherings. However, the deposit reaches your brokerage account on a Tuesday in March or a Friday in September, and somewhere in suburban New Jersey, a finance team has completed the same task every quarter since John F. Kennedy was alive.
Depending on what you’re attempting to construct, that may or may not be sufficient. It’s difficult to argue against attending for investors who gauge success in terms of restful nights.
